Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17590140 | 1.00 | CA2 (0.33) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL18653832 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HPGDABCB1 | |
| SCHEMBL13498248 | 0.74 | CA2 (0.42) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL13129980 | 0.73 | CA2 (0.41) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL13129913 | 0.73 | CA2 (0.41) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL15975397 | 0.73 | CA2 (0.38) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL2672023 | 0.73 | CA2 (0.60) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL17590138 | 0.72 | LGALS8 (0.32) | ALDH1A1 | |
| SCHEMBL4546316 | 0.72 | LGALS8 (0.32) | ALDH1A1 | |
| SCHEMBL2672026 | 0.69 | CA2 (0.56) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987430-B2 | Efficient and scalable process for the manufacture of fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130102764-A1 | PROCESS FOR PERPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-8420790-B2 | Efficient and scalable process for the manufacture of Fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8288515-B2 | Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110105418-A1 | PROCESS FOR PREPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105418-A1 | PROCESS FOR PREPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | F11, TFPI, STS | CA2 1106/4885CA1 638/4885CA9 633/4885 |
| US-20130102764-A1 | PROCESS FOR PERPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | TFPI, PLG, PCSK6 | CA2 1018/4885CA1 776/4885CA9 445/4885 |
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | CA2 519/4885CA1 817/4885CA9 465/4885 |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | CA2 519/4885CA1 817/4885CA9 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.